The stock of Enliven Therapeutics Inc (ELVN) has gone down by -12.05% for the week, with a 3.13% rise in the past month and a -6.73% drop in the past quarter. The volatility ratio for the week is 6.81%, and the volatility levels for the past 30 days are 6.02% for ELVN. The simple moving average for the past 20 days is 4.98% for ELVN’s stock, with a -12.15% simple moving average for the past 200 days.
Is It Worth Investing in Enliven Therapeutics Inc (NASDAQ: ELVN) Right Now?
Company’s 36-month beta value is 0.81.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ELVN is 32.22M, and currently, short sellers hold a 20.19% ratio of that floaft. The average trading volume of ELVN on June 12, 2025 was 344.89K shares.
ELVN) stock’s latest price update
The stock price of Enliven Therapeutics Inc (NASDAQ: ELVN) has plunged by -9.65 when compared to previous closing price of 21.70, but the company has seen a -12.05% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-22 that BOULDER, Colo., May 22, 2025 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences: TD Cowen’s 6th Annual Oncology Innovation Summit: Insights from ASCO & EHA Format: Fireside ChatDate: Tuesday, May 27, 2025 Time: 1:00 p.m.
Analysts’ Opinion of ELVN
Many brokerage firms have already submitted their reports for ELVN stocks, with BTIG Research repeating the rating for ELVN by listing it as a “Buy.” The predicted price for ELVN in the upcoming period, according to BTIG Research is $42 based on the research report published on December 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ELVN reach a price target of $37. The rating they have provided for ELVN stocks is “Buy” according to the report published on September 09th, 2024.
Robert W. Baird gave a rating of “Outperform” to ELVN, setting the target price at $32 in the report published on June 11th of the previous year.
ELVN Trading at 6.64% from the 50-Day Moving Average
After a stumble in the market that brought ELVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.72% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELVN starting from Patel Anish, who sale 6,667 shares at the price of $20.34 back on Jun 09 ’25. After this action, Patel Anish now owns 303,309 shares of Enliven Therapeutics Inc, valued at $135,574 using the latest closing price.
Patel Anish, the Officer of Enliven Therapeutics Inc, proposed sale 6,667 shares at $20.74 during a trade that took place back on Jun 09 ’25, which means that Patel Anish is holding shares at $138,274 based on the most recent closing price.
Stock Fundamentals for ELVN
The total capital return value is set at -0.38. Equity return is now at value -31.30, with -29.39 for asset returns.
Currently, EBITDA for the company is -88.47 million with net debt to EBITDA at 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.06.
Conclusion
In a nutshell, Enliven Therapeutics Inc (ELVN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
